Background: Optical coherence tomography (OCT) is a non-invasive imaging technique that is used to obtain high-resolution cross-sectional images of the retina. Diabetic choroidopathy refers to the presence of choroidal abnormalities in individuals with diabetes, which may contribute to the deterioration of visual acuity. Aim: To assess the subfoveal choroidal thickness (SFCT) and its relation with visual acuity in patients with diabetic macular edema (DME) after and before receiving intravitreal injections of ranibizumab. This assessment will be conducted using improved depth spectral-domain imaging (EDI-OCT) with a focus on controlling for confounding variables. Patients and Methods: The study included a total of 50 participants, composeding of 27 females and 23 men, all between the ages of 70 and 50. These individuals were diagnosed with DME, type 2 diabetes mellitus (DM) and had central foveal thickness not exceeding 450 microns as dete-rmined using OCT. The SFCT was assessed using the manual caliper function inside the Heidelberg Spectralis OCT program after and before the administration of intravitreal ranibizumab injections at three and one months. Results: The differences in best-corrected visual acuity (BCVA) between the postoperative and preoperative three-month measurements were found to be statistically important (p = 0.001). Similarly, the variances in SFCT between the postoperative and preoperative three-month measurements were also found to be statistically important (p = 0.001). Conclusions: A reduction in the average SFCT has been observed after Anti-VEGF therapy, additionally, there is evidence of improved BCVA.